Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atovaquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atovaquone SCHEMBL20769805 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL637069 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL1542719 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL9975142 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL29559044 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8848607 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8851283 | 0.90 | MAPT (0.67) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL21695 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL1649508 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL28082527 | 0.89 | MAPT (0.73) | MAPTKMT2AMEN1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16293 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094672-A | Method for treating and preventing non-viral tick-borne diseases and symptoms thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260097004-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MAST CELL-MEDIATED INFLAMMATORY DISEASES | CHU LEI (CN) | 2026-04-09 | — | — | US | claimed |
| US-12594283-B2 | Mitochondria-targeted atovagone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12582667-B2 | Compositions and methods to treat metastatic gastrointestinal cancer | THE ROCKEFELLER UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| US-20260063633-A1 | Methods and Reagents for Toxoplasma Infection Diagnosis | MCLEOD RIMA (US) | 2026-03-05 | — | — | US | claimed |
| CN-121570586-A | Phototherapy nano-drug with mitochondria/STAT 3 protein double-site targeting function, and preparation method and application thereof | 安徽医科大学 | 2026-02-27 | — | — | CN | claimed |
| EP-4698165-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF NON-VIRAL TICK-BORNE DISEASES AND SYMPTOMS THEREOF | 60 Degrees Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-1996016652-A2 | USE OF RIFABUTIN AND A COMBINATION OF RIFABUTIN AND ATOVAQUONE IN THE TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| WO-1996013254-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ATOVAQUONE | GLAXO WELLCOME HOUSE (GB) | 1996-05-09 | — | — | WO | claimed |
| WO-1996004924-A1 | IMPROVED ANTIINFECTIVE POLYOXYPROPYLENE/POLYOXYETHYLENE COPOLYMERS AND METHODS OF USE | CYTRX CORPORATION (US) | 1996-02-22 | — | — | WO | claimed |
| EP-0675711-A1 | ATOVAQUONE PHARMACEUTICAL COMPOSITIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-10-11 | — | — | EP | claimed |
| WO-1995015182-A1 | ANTIINFECTIVE COMPOSITIONS AND METHODS OF USE | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| CN-1103290-A | Pharmaceutical preparation | WELLCOME FOUND (GB) | 1995-06-07 | — | — | CN | claimed |
| WO-1994014426-A1 | ATOVAQUONE PHARMACEUTICAL COMPOSITIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | claimed |
| EP-0572615-A1 | MEDICAMENT FOR TREATMENT OF PROTOZOAL INFECTIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-08 | — | — | EP | claimed |
| WO-1993011756-A1 | MEDICAMENT FOR TREATMENT OF PROTOZOAL INFECTIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-06-24 | — | — | WO | claimed |
| US-4981874-A | PREVENTING PNEUMOXYSTIS PNEUMONIA IN AIDS PATIENTS | LATTER VICTORIA S (GB) | 1991-01-01 | — | — | US | claimed |